Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989986 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29591196 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL1709129 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL30074491 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL5323666 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29792137 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL29350883 | 1.00 | KMT2A (0.52) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL22069879 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL20732318 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 | |
| SCHEMBL31133584 | 0.96 | PTPN1 (0.49) | KMT2AMDM4TP53PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340472-B | Glutamic acid derivative and synthesis method and application thereof | 合肥工业大学 | 2024-05-07 | — | — | CN | claimed |
| CN-115340472-A | Glutamic acid derivative and synthetic method and application thereof | 合肥工业大学 | 2022-11-15 | — | — | CN | claimed |
| CN-120040554-A | Cyclic peptide liver targeting compound, pharmaceutical composition and application thereof | 云合智药（苏州）生物科技有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | Sumitomo Pharma Co., Ltd. (JP) | 2025-05-27 | — | — | US | disclosed |
| CN-119954773-A | PSMA compounds, pharmaceutical compositions comprising the same and uses thereof | 苏州威智创科生物有限公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025092841-A1 | PSMA COMPOUND, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF | 山东威智知科药业有限公司 | 2025-05-08 | — | — | WO | disclosed |
| WO-2025070720-A1 | PEPTIDE | ペプチドリーム株式会社 | 2025-04-03 | — | — | WO | disclosed |
| CN-119490560-A | Tetrafunctional boron medicine compound, preparation method, application and pharmaceutical composition | 东莞市人民医院 | 2025-02-21 | — | — | CN | disclosed |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | REGENERON PHARMA (US) | 2024-12-12 | — | — | US | disclosed |
| CN-114929729-B | Nucleic acid complex and pharmaceutical composition containing the same | 卫材R&D管理有限公司 | 2024-12-03 | — | — | CN | disclosed |
| EP-4464341-A2 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München, in Vertretung des Freistaates Bayern (DE) | 2024-11-20 | — | — | EP | disclosed |
| WO-2017214491-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214491-A1 | SILANOL BASED THERAPEUTIC PAYLOADS | BLINKBIO, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-6281352-B1 | ANTIINFLAMMATORY AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-08-28 | — | — | US | disclosed |
| EP-0863885-A2 | NOVEL MACROCYCLIC COMPOUNDS AS METALLOPROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997018207-A2 | NOVEL MACROCYCLIC COMPOUNDS AS METALLOPROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | KMT2A 1005/4885MDM4 2319/4885TP53 92/4885 |
| US-12312419-B2 | Hemiasterlin derivative having cysteine residue | SHBG, CYP11A1, CYP11B1 | KMT2A 3110/4885MDM4 2803/4885TP53 1696/4885 |
| US-20240408223-A1 | HYDROPHILIC LINKERS FOR ANTIBODY DRUG CONJUGATES | CD44, CD47, EPCAM | KMT2A 936/4885MDM4 3252/4885TP53 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.